Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Valsartan
  • 1.4.3 Irbesartan
  • 1.4.4 Candesartan Cilexetil
  • 1.4.5 Eprosartan
  • 1.4.6 Irbesartan
  • 1.4.7 Telmisartan
  • 1.4.8 losartan
  • 1.4.9 Olmesartan Medoxomil
  • 1.4.10 Allisartan isoproxil
• 1.5 Market by Application
  • 1.5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2014-2025)
  • 1.5.2 High Blood Pressure
  • 1.5.3 Congestive Heart Failure
  • 1.5.4 Left Ventricular Hypertrophy
  • 1.5.5 Atherosclerosis
  • 1.5.6 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size
• 2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Growth Trends by Regions
  • 2.2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions (2014-2025)
  • 2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by by Players
  • 3.1.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by by Players (2014-2019)
  • 3.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
• 3.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players Head office and Area Served
• 3.3 Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product/Solution/Service
• 3.4 Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2014-2019)
• 4.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2014-2019)

5 United States

• 5.1 United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
• 5.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in United States
• 5.3 United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
• 5.4 United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

6 Europe

• 6.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
• 6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Europe
• 6.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
• 6.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

7 China

• 7.1 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
• 7.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in China
• 7.3 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
• 7.4 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

8 Japan

• 8.1 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
• 8.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Japan
• 8.3 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
• 8.4 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
• 9.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Southeast Asia
• 9.3 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
• 9.4 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

10 India

• 10.1 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
• 10.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in India
• 10.3 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
• 10.4 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

11 Central & South America

• 11.1 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
• 11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Central & South America
• 11.3 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
• 11.4 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

12 International Players Profiles

• 12.1 Pfizer
  • 12.1.1 Pfizer Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
  • 12.1.4 Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
  • 12.1.5 Pfizer Recent Development
• 12.2 Novartis
  • 12.2.1 Novartis Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
  • 12.2.4 Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
  • 12.2.5 Novartis Recent Development
• 12.3 Merck
  • 12.3.1 Merck Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
  • 12.3.4 Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
  • 12.3.5 Merck Recent Development
• 12.4 AstraZeneca
  • 12.4.1 AstraZeneca Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
  • 12.4.4 AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
  • 12.4.5 AstraZeneca Recent Development
• 12.5 Jhonson and Johnson
  • 12.5.1 Jhonson and Johnson Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
  • 12.5.4 Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
  • 12.5.5 Jhonson and Johnson Recent Development
• 12.6 Eli Lilly
  • 12.6.1 Eli Lilly Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
  • 12.6.4 Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
  • 12.6.5 Eli Lilly Recent Development
• 12.7 Sanofi
  • 12.7.1 Sanofi Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
  • 12.7.4 Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
  • 12.7.5 Sanofi Recent Development
• 12.8 Bristol-Myers Squibb
  • 12.8.1 Bristol-Myers Squibb Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
  • 12.8.4 Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
  • 12.8.5 Bristol-Myers Squibb Recent Development
• 12.9 Bayer
  • 12.9.1 Bayer Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
  • 12.9.4 Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
  • 12.9.5 Bayer Recent Development
• 12.10 GSK
  • 12.10.1 GSK Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
  • 12.10.4 GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
  • 12.10.5 GSK Recent Development
• 12.11 Teva Pharmaceutical
• 12.12 Shenzhen Salubris Pharmaceuticals
• 12.13 Sun Pharmaceutical
• 12.14 Mylan
• 12.15 Alembic Pharmaceuticals
• 12.16 Lupin
• 12.17 Aurobindo Pharma
• 12.18 Amneal Pharmaceuticals
• 12.19 Boehringer Ingelheim

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer